Amarin Corporation PLC (AMRN.O)

AMRN.O on Consolidated Issue listed on NASDAQ Global Market

2.18USD
29 Jul 2015
Change (% chg)

$0.03 (+1.40%)
Prev Close
$2.15
Open
$2.14
Day's High
$2.26
Day's Low
$2.13
Volume
587,391
Avg. Vol
1,978,044
52-wk High
$3.33
52-wk Low
$0.78

AMRN.O

Chart for AMRN.O

About

Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin's lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $378.93
Shares Outstanding(Mil.): 176.25
Dividend: --
Yield (%): --

Financials

  AMRN.O Industry Sector
P/E (TTM): -- 434.54 39.84
EPS (TTM): -0.37 -- --
ROI: -34.02 -5.70 15.61
ROE: -- -5.69 16.64
Search Stocks

Amarin asks judge to protect off-label promotion of fish oil pill

- Lawyers for Irish drugmaker Amarin PLC on Tuesday urged a Manhattan federal judge to block the Food and Drug Administration from restricting Amarin's right to promote off-label use of its fish oil pill, arguing that any such restriction would violate the First Amendment.

07 Jul 2015

FDA undercuts Amarin lawsuit on fish oil drug information

- The U.S. Food and Drug Administration, responding to a lawsuit filed by Amarin Corp over information the company wants to disseminate for its fish oil drug, said it had no objection to Amarin sharing the data with healthcare providers.

09 Jun 2015

FDA undercuts Amarin lawsuit on fish oil drug information

- The U.S. Food and Drug Administration, responding to a lawsuit filed by Amarin Corp over information the company wants to disseminate for its fish oil drug, said it had no objection to Amarin sharing the data with healthcare providers.

09 Jun 2015

FDA undercuts Amarin lawsuit on fish oil drug information

June 9 - The U.S. Food and Drug Administration, responding to a lawsuit filed by Amarin Corp over information the company wants to disseminate for its fish oil drug, said it had no objection to Amarin sharing the data with healthcare providers.

09 Jun 2015

U.S. court grants exclusivity for Amarin's Vascepa

- A U.S. district court has ruled that Amarin Corp's fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a U.S. Food and Drug administration decision.

28 May 2015

U.S. court grants exclusivity for Amarin's Vascepa

May 28 - A U.S. district court has ruled that Amarin Corp's fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a U.S. Food and Drug administration decision.

28 May 2015

Irish drugmaker sues FDA under First Amendment

- Amarin Corp Plc, an Irish drugmaker trying to expand the market for its fish-oil pill, has sued the U.S. Food and Drug Administration for restricting its right to promote the drug for unapproved, or off-label, use.

07 May 2015

CORRECTED-Irish drugmaker sues FDA under First Amendment

May 7 - Amarin Corp Plc, an Irish drugmaker trying to expand the market for its fish-oil pill, has sued the U.S. Food and Drug Administration for restricting its right to promote the drug for unapproved, or off-label, use.

07 May 2015

Amarin sues U.S. FDA on free speech grounds over off-label speech

May 7 - Amarin Corp Plc filed suit against the U.S. Food and Drug Administration on Thursday for restricting its right to promote its fish oil drug Vascepa for an unapproved, or off-label, use.

07 May 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks